Advertisement
U.S. markets closed
  • S&P 500

    5,123.41
    -75.65 (-1.46%)
     
  • Dow 30

    37,983.24
    -475.84 (-1.24%)
     
  • Nasdaq

    16,175.09
    -267.10 (-1.62%)
     
  • Russell 2000

    2,003.17
    -39.43 (-1.93%)
     
  • Crude Oil

    85.45
    +0.43 (+0.51%)
     
  • Gold

    2,360.20
    -12.50 (-0.53%)
     
  • Silver

    27.97
    -0.28 (-0.99%)
     
  • EUR/USD

    1.0646
    -0.0085 (-0.79%)
     
  • 10-Yr Bond

    4.4990
    -0.0770 (-1.68%)
     
  • GBP/USD

    1.2451
    -0.0104 (-0.83%)
     
  • USD/JPY

    153.2400
    +0.0370 (+0.02%)
     
  • Bitcoin USD

    67,068.68
    -3,105.48 (-4.43%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,995.58
    +71.78 (+0.91%)
     
  • Nikkei 225

    39,523.55
    +80.92 (+0.21%)
     

Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Bristol-Myers Squibb Co (NYSE: BMY) shares spiked 4.5 percent Tuesday on news that Carl Icahn bought a stake in the company. According to the Wall Street Journal, Icahn allegedly considers Bristol-Myers a potential takeover target.

Earlier Tuesday, Bristol-Myers reported a $2 billion accelerated buyback.

The investor's expectation corroborates a January Bloomberg report acknowledging Bristol-Myers' fall from the fourth-best to the ninth-best biopharmaceutical company in the US. The company’s struggle to push its lung cancer drug, Opdivo, set it well behind competitor Merck & Co., Inc. (NYSE: MRK) and prompted a two-year plunge in stock value.

Now, as a more affordable company with a promising blood thinner and a potential use for Opdivo in melanoma and kidney cancer treatments, Bristol-Myers is well positioned for a buyout.

Related Link: Here's What Merck's Keytruda News Means For Bristol-Myers

Jefferies analyst Jeffrey Holford suggested in a recent note the company may appeal to Sanofi SA (ADR) (NYSE: SNY), Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE) and Novartis AG (ADR) (NYSE: NVS) — but not likely Amgen, Inc. (NASDAQ: AMGN) or Gilead Science, Inc. (NASDAQ: GILD).

Meanwhile, Deutsche Bank analysts proposed Pfizer would likely be deterred by the short-term risk of immuno-oncology trials and wouldn't make a bid.

Bristol-Myers stock waned from its post-news peak and traded at $54.78 at the time of publication.

See more from Benzinga

© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement